A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia
Abstract Objective WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. Methods A 16‐week randomized double‐blin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | Aging Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/agm2.12230 |
| _version_ | 1797974178425470976 |
|---|---|
| author | Junguang Liu Dennis Chang Dennis Cordato Kien Lee Hugh Dixson Alan Bensoussan Daniel Kam Yin Chan |
| author_facet | Junguang Liu Dennis Chang Dennis Cordato Kien Lee Hugh Dixson Alan Bensoussan Daniel Kam Yin Chan |
| author_sort | Junguang Liu |
| collection | DOAJ |
| description | Abstract Objective WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. Methods A 16‐week randomized double‐blind, placebo‐controlled trial was carried out in the setting of a memory disorder clinic at a single center. Patients with vascular dementia diagnosed clinically but supported by imaging and other investigations were invited to participate. The diagnoses were based on the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria. An independent blinded assessor evaluated the effects of the formula. Intervention group was compared to the control group. A subgroup of participants was randomly chosen for further evaluation of cerebral perfusion by single photon emission computed tomography scans post‐treatment. Results Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. Sixty‐two participants were included in final analysis. Alzheimer's Disease Assessment Scale – Cognitive Portion (ADAS‐cog) was the primary outcome. By week 16, the mean ADAS‐cog reduced from 24.48 to 20.30 (mean reduction = 4.18) for those in the treatment group, and from 18.98 to 17.81 (mean reduction = 1.18) for those in the placebo group. The difference in mean reduction of ADAS‐cog was −3.00 (95% confidence interval [CI] = −4.910 to −1.100) in favor of the treatment group. Secondary outcomes of activities of daily living and quality of life measures also showed significant difference. In the perfusion scan analysis, the difference in the change in cerebral blood flow (t‐scores) pre‐ and post‐treatment between the intervention group (n = 7) and the placebo group (n = 11) was statistically significant (P < 0.001). Conclusion In this randomized, double‐blind placebo‐controlled trial, we demonstrated significant differences in improvement in cognitive function and activities of daily living. The clinical improvement is corroborated with improvement in cerebral perfusion in a subset of participants. |
| first_indexed | 2024-04-11T04:15:56Z |
| format | Article |
| id | doaj.art-2fd8b64a21614da593b82bc78e9a0e60 |
| institution | Directory Open Access Journal |
| issn | 2475-0360 |
| language | English |
| last_indexed | 2024-04-11T04:15:56Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Aging Medicine |
| spelling | doaj.art-2fd8b64a21614da593b82bc78e9a0e602022-12-31T12:32:13ZengWileyAging Medicine2475-03602022-12-015424625610.1002/agm2.12230A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementiaJunguang Liu0Dennis Chang1Dennis Cordato2Kien Lee3Hugh Dixson4Alan Bensoussan5Daniel Kam Yin Chan6NICM Health Research Institute Western Sydney University Westmead New South Wales AustraliaNICM Health Research Institute Western Sydney University Westmead New South Wales AustraliaDepartment of Neurology Liverpool Hospital Liverpool New South Wales AustraliaDepartment of Nuclear Medicine and Ultrasound Bankstown‐Lidcombe Hospital Bankstown New South Wales AustraliaDepartment of Nuclear Medicine and Ultrasound Bankstown‐Lidcombe Hospital Bankstown New South Wales AustraliaNICM Health Research Institute Western Sydney University Westmead New South Wales AustraliaNICM Health Research Institute Western Sydney University Westmead New South Wales AustraliaAbstract Objective WeiNaoKang (or SaiLuoTong) is an herbal formula consisting of ginkgo, ginseng, and saffron. Our objective was to investigate if WeiNaoKang could improve cognitive function and cerebral perfusion in patients suffering from vascular dementia. Methods A 16‐week randomized double‐blind, placebo‐controlled trial was carried out in the setting of a memory disorder clinic at a single center. Patients with vascular dementia diagnosed clinically but supported by imaging and other investigations were invited to participate. The diagnoses were based on the National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria. An independent blinded assessor evaluated the effects of the formula. Intervention group was compared to the control group. A subgroup of participants was randomly chosen for further evaluation of cerebral perfusion by single photon emission computed tomography scans post‐treatment. Results Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. Sixty‐two participants were included in final analysis. Alzheimer's Disease Assessment Scale – Cognitive Portion (ADAS‐cog) was the primary outcome. By week 16, the mean ADAS‐cog reduced from 24.48 to 20.30 (mean reduction = 4.18) for those in the treatment group, and from 18.98 to 17.81 (mean reduction = 1.18) for those in the placebo group. The difference in mean reduction of ADAS‐cog was −3.00 (95% confidence interval [CI] = −4.910 to −1.100) in favor of the treatment group. Secondary outcomes of activities of daily living and quality of life measures also showed significant difference. In the perfusion scan analysis, the difference in the change in cerebral blood flow (t‐scores) pre‐ and post‐treatment between the intervention group (n = 7) and the placebo group (n = 11) was statistically significant (P < 0.001). Conclusion In this randomized, double‐blind placebo‐controlled trial, we demonstrated significant differences in improvement in cognitive function and activities of daily living. The clinical improvement is corroborated with improvement in cerebral perfusion in a subset of participants.https://doi.org/10.1002/agm2.12230cerebral perfusion scandementiarandomized controlled trialSaiLuoTongvascular dementiaWeiNaoKang |
| spellingShingle | Junguang Liu Dennis Chang Dennis Cordato Kien Lee Hugh Dixson Alan Bensoussan Daniel Kam Yin Chan A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia Aging Medicine cerebral perfusion scan dementia randomized controlled trial SaiLuoTong vascular dementia WeiNaoKang |
| title | A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia |
| title_full | A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia |
| title_fullStr | A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia |
| title_full_unstemmed | A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia |
| title_short | A pilot randomized controlled trial of WeiNaoKang (SaiLuoTong) in treating vascular dementia |
| title_sort | pilot randomized controlled trial of weinaokang sailuotong in treating vascular dementia |
| topic | cerebral perfusion scan dementia randomized controlled trial SaiLuoTong vascular dementia WeiNaoKang |
| url | https://doi.org/10.1002/agm2.12230 |
| work_keys_str_mv | AT junguangliu apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT dennischang apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT denniscordato apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT kienlee apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT hughdixson apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT alanbensoussan apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT danielkamyinchan apilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT junguangliu pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT dennischang pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT denniscordato pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT kienlee pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT hughdixson pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT alanbensoussan pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia AT danielkamyinchan pilotrandomizedcontrolledtrialofweinaokangsailuotongintreatingvasculardementia |